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analysis revealed that the CD8+/CD27− and CD8+/CD57+ 
effector T cell fractions strongly increase in NF1 patients 
with low tumor load and decrease to levels below control in 
patients with high tumor load. Moreover, increased produc-
tion of IL2, IFN-γ and TNF-α was found in T cells of NF1 
patients upon phorbol-12-myristate acetate (PMA) stimu-
lation compared to healthy controls. The data indicate that 
decreasing CD8+/CD57+ and CD27− T cell fractions cor-
respond to increasing tumor load in NF1 patients, poten-
tially making these populations useful marker for internal 
tumor burden.
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CD  Cluster of differentiation
DMSO  Dimethylsulfoxide
ECD  Electron coupled dye
FACS  Fluorescence-activated cell sorting
FBS  Fetal bovine serum
FITC  Fluorescein isothiocyanate
GAP  GTP activating domain
GTP  Guanosine triphosphate
HLA  Human histocompatibility leukocyte antigen
HLA-DR  HLA antigen D related
IFN  Interferon
IL  Interleukin
MRI  Magnetic resonance imaging
NF1  Neurofibromatosis type 1
NF1/Nf1  Neurofibromin gene (human/mouse)
PBMC  Peripheral blood mononuclear cells
PBS  Phosphate-buffered saline
Abstract Neurofibromatosis type 1 (NF1) is a hereditary 
tumor syndrome caused by mutations of the NF1 gene and 
resulting dysregulation of the Ras-pathway. In addition to 
peripheral nerve tumors, affected tissues include the mus-
culoskeletal and cardiovascular system. The immune sys-
tem has recently been suggested as a possible modulator 
NF1-related phenotypes. Therefore, we determined the 
immune phenotype in NF1 patients and investigated its 
relationship with the phenotypic severity of NF1-related 
tumor manifestations. We quantified global leukocytes and 
lymphocyte subpopulations of peripheral blood from 37 
NF1 patients and 21 healthy controls by flow cytometry. 
To associate immune phenotype with tumor phenotype, all 
NF1 patients underwent whole-body magnetic resonance 
imaging and total internal tumor volume was calculated. 
The immunophenotypes were compared among four NF1 
groups with different total internal tumor burdens and 
between NF1 patients and non-NF1 subjects. We found 
that NF1 patients show a generalized lymphopenia. Closer 
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PerCP  Peridinin chlorophyll protein
PMA  Phorbol myristate acetate
PNF  Plexiform neurofibroma
STIR  Short-Ti inversion-recovery
T cell  Thymocyte
TNF  Tumor necrosis factor
Introduction
Neurofibromatosis type 1 (NF1) is a rare autosomal domi-
nant tumor syndrome, with an estimated incidence at birth 
of 1 in 3000 [1] and complete penetrance. NF1 is caused 
by heterozygous mutations in the NF1 gene, which codes 
for the tumor suppressor protein neurofibromin acting as 
a Ras-negative regulator via its Ras-guanosine triphos-
phate (GTP) activating domain (GAP)-domain. Mutations 
of NF1 lead to increased Ras-activity in affected cells [2, 
3]. NF1 patients are prone to develop multiple phenotypic 
manifestations involving the skin, peripheral and central 
nervous system, musculoskeletal system and cardiovas-
cular system. Multiple neurofibromas are the hallmark of 
the disease and affect almost all patients. Although benign, 
neurofibromas can cause severe secondary symptoms such 
as disfigurement and pain. Musculoskeletal phenotypes of 
NF1 include scoliosis, long-bone pseudarthrosis and gen-
eralized osteoporosis; cardiovascular symptoms may result 
from involvement of the heart itself or of cerebral, coro-
nary, renal or other arteries. In addition, cognitive impair-
ment and other neuropsychological problems are common 
[4]. Expressivity of the NF1 phenotype is highly variable 
and risk assessment problematic due to lack of predictive 
markers.
There is increasing evidence from animal models and 
clinical observations, supporting an association of immune 
phenotypes with several NF1 phenotypes. Abundant mast 
cells were recognized as a frequent histopathological fea-
ture of benign neurofibromas more than 35 years ago [5], 
an observation that has been repeatedly confirmed [6–8]. 
Although suggested that these inflammatory cells may be 
involved in the pathogenesis of neurofibromas in patients 
with NF1 [9], it was the observation that myeloid malig-
nancies, which occur much more often than expected in 
children with NF1, frequently exhibit loss of activity of 
both NF1 alleles in people with NF1 [10, 11] that delivered 
evidence for the functional importance of neurofibromin in 
myeloid cells. The subsequent demonstration that devel-
opment of neurofibromas in mouse models required Nf1 
haploinsufficiency in myeloid cells of the tumor microenvi-
ronment [12–15] established the central role of these bone 
marrow-derived cells in the pathogenesis of NF1.
Likewise, the hematopoietic microenvironment has been 
shown to be involved in development of both NF1 vas-
cular disease and NF1 bone disease. For example, NF1-
associated vascular disease was associated with a striking 
increase in vascular inflammation and vascular monocytes 
in humans [16]. Experiments in a murine model have dem-
onstrated that vascular neointima formation is enhanced by 
myeloid cells lacking Nf1 [17]. Similarly, deficient fracture 
healing and other skeletal manifestations of NF1 have been 
shown to require the presence of Nf1 haploinsufficiency in 
bone marrow mononuclear cells in a mouse model [18]. 
In addition, an increase in brain microglia in NF1 patients 
has been reported [19]. The available data substanti-
ate increased circulating monocyte numbers and higher 
migratory and proliferative capacities of macrophages in 
NF1 patients and in NF1-deficient mice [8, 12–17]. It was 
furthermore demonstrated that NF1-deficient mice dis-
play aberrations in T cell development and function, with 
reduced proliferative responsiveness to interleukin2 and 
modulated numbers of naïve T cells [20, 21]. Of note, 
HLA-DR was found upregulated in NF1−/− Schwann cells, 
while it is almost undetectable in normal Schwann cells 
[22]. Moreover, aberrant plasma cytokine levels in NF1 
patients were found in several studies, indicating general-
ized immunological imbalances with a tendency to develop 
a systemic inflammatory environment [23–26].
In summary, there is growing evidence for an altered 
hematopoietic phenotype due to NF1 haploinsufficiency, 
which may play a role in the modulation of one or several 
of the multiple NF1 phenotypes such as vascular disease, 
idiopathic hypertension, fracture healing and other skeletal 
manifestations as well as tumorigenesis. However, asso-
ciation of immunological and clinical phenotypes has not 
yet been systematically assessed with quantifiable clinical 
data in a larger number of NF1 patients. In particular, we 
were interested in assessing the lymphocyte fraction of the 
adaptive hematopoietic cell repertoire and its association 
with the highly variable tumor phenotype in NF1 patients. 
Therefore, we profiled the cellular immune phenotype of 
NF1 patients and correlated it with the quantified internal 
tumor volume of plexiform neurofibromas (PNF) obtained 
by magnetic resonance imaging (MRI) of the whole body.
Materials and methods
Patients and samples
Adults and children with NF1 were recruited after informed 
consent at the University Hospital Hamburg-Eppendorf. 
Blood samples from adult healthy subjects were obtained at 
Charité University Medicine Berlin after informed consent. 
Altogether, 37 adult NF1 patients, 9 NF1 patients under 
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18 years and 21 healthy subjects were included. All NF1 
patients were clinically diagnosed according to published 
guidelines and criteria [27]. Patients with microdeletions 
involving the NF1 gene, astrocytoma, optical pathway gli-
oma, spinal tumors and schwannoma were excluded from 
the study. The study was approved by the internal review 
board (Ethics Committee of the Ärztekammer Hamburg 
number OB-089/04).
For flow cytometry, the following groups were used: 
healthy control subjects (n = 21, age range 18–60 years, 
mean 36 years, 11 male, 10 female) and NF1 patients 
(n = 37, only subjects over 20 years of age were included, 
range 20–66 years, mean 36 years, 18 male, 19 female). 
Correlation with tumor load was according to the follow-
ing groups: no internal PNF tumors (n = 6), low tumor 
load (tumor volume <99 cm3; n = 11), medium tumor 
load (tumor volume 100–500 cm3; n = 9), high tumor load 
(tumor volume >500 cm3; n = 11).
Blood differential test
May–Grunwald–Giemsa-stained-whole-blood smears were 
microscopically examined independently by two persons 
using standard routine protocols in a double-blinded fash-
ion. Standard reference ranges of leukocyte populations 
were used for comparison [28].
Flow cytometry
FACS of PBMC was used to analyze the ratio of different 
lymphocyte T cell populations. PBMC were prepared from 
15 ml to 20 ml venous blood samples collected in sodium cit-
rate as anticoagulant by density gradient in Leucosep™ tubes 
and Ficoll-Paque Plus solution (Amersham Biosciences) 
according to manufacturer’s instructions. PBMC were 
washed with sterile PBS (Biochrom), re-suspended, counted 
and cryopreserved with 10 % DMSO in FBS (5x10E6 cells/
vial) and stored in liquid nitrogen. Flow cytometric analyses 
were conducted with FITC-, PE-, PE-cyanin 7 (PE-Cy7)-, 
PerCP-, electron coupled dye (ECD)-, Alexa Fluor® 647-, 
Alexa Fluor 700-, Horizon™ V450-, Horizon™ V500-, allo-
phycocyanin (APC)-, APC cyanin 7 (APC-Cy7)-, Qdot® 655 
nanocrystal- and allophycocyanin-conjugated antibodies. 
The following antibodies were used: Anti-human CD8 (Life 
Technologies), CD336 (Becton–Dickinson), CD314 (Beck-
man Coulter), CD3 (Life Technologies), CD335 (R&D Sys-
tems), CD62L (Beckman Coulter), CD56 (Becton–Dickin-
son), CD4 (Becton–Dickinson), CD16 (Becton–Dickinson), 
CD25 (Becton–Dickinson), CD127(eBioscience), HLA-DR 
(Becton–Dickinson), CD57 (Miltenyi Biotec), CD45RO 
(Becton–Dickinson), CD27 (Life Technologies). Live/dead-
discrimination staining dye (Life Technologies) was added to 
exclude dead cells. After thawing, cell number and viability 
was microscopically assessed with trypan blue (Sigma) 
before surface staining. Cells were incubated for 30 min at 
2–8 °C and washed afterward. Cells were measured with a 
LSR-II flow cytometer (Becton–Dickinson), and FACS data 
were analyzed using FlowJo software (Tree Star Inc.). The 
following panels were used: T cells (TH/Tcyt) CD3
+ CD4/
CD8; naïve T cells CD4+/CD45RO−; effector/central mem-
ory T cells CD45RO/CD62L; naturally occurring regulatory 
T cells CD25+/CD127lo; late activation marker memory T 
cells CD4/CD8/CD57+; late differentiation T cells CD27−; 
early activation marker expressing T cells HLA-DR; natural 
killer (NK) cells CD3/CD56; cytotoxic NK cells CD16+/
CD56dim; regulatory NK cells CD16+CD56bright.
Tumor quantification
Whole-body MRI was performed in NF1 patients to quan-
tify total internal tumor volume. MRI and calculation of 
total tumor volume were performed in analogy to previous 
studies [29, 30]. All patients underwent an identical scan 
protocol with the same parameters for slice thickness, gap, 
orientation, field of view, imaging matrix, image resolution, 
echo time, repetition time and inversion time (Siemens 
Avanto 1.5T). The subjects were imaged in a supine posi-
tion from head to knee in four steps (head, thorax, abdo-
men and legs) in accordance with the maximum range of 
table movement. Slice thickness is 5–10 mm without skips 
between slices. MRI analysis was performed by an experi-
enced radiologist and a physician trained in image analysis 
of NF1 associated tumors. The analysis was carried out in 
a blinded manner. Tumor segmentation and volumetry were 
performed semiautomatically with the heuristics-based 
software MEDx (V 3.44) using fat-suppressed T2-short-Ti 
inversion-recovery (STIR) sequences. Differences in sig-
nal intensity of neurofibroma tissue and surrounding tis-
sue were used to define tumor margins on axial slices. The 
method used for this automated volumetric analysis is sen-
sitive (it detects volume changes as small as 10 %), repro-
ducible (coefficient of variation 0.6–5.6 %) and produces 
results similar to manual tumor tracings (R = 0.999).
Whole-body cutaneous and subcutaneous neurofibroma 
burden were independently examined by two observers 
and averages used. Tumor number was estimated within 
set ranges of (0, 1–10, 11–50, 51–100, 101–500, 500+, 
1000+).
Intracellular cytokine staining
Cytokine production was measured by CD4 and CD8 cells 
from age- and gender-matched NF1 patients and healthy 
controls after stimulation. PBMC were stimulated for 4 h 
with PMA/ionomycin (Sigma), and cytokine secretion was 
blocked with brefeldin A (BD Biosciences). Cell fixation 
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and permeabilization were carried out with the BD Fixa-
tion/Permeabilization Solution kit. Antibodies directed 
against IL-2, TNF-α and IFN-γ (BD Biosciences) were 
used to label intracellular cytokines for FACS analysis with 
a LSR-II flow cytometer (Becton–Dickinson), and data 
were analyzed using FlowJo software (Tree Star Inc.).
Statistical analysis
To verify all data for normal distribution, the Kolmogorov–
Smirnov test was performed. Stratified patient groups were 
compared using the Mann–Whitney U test for continuous 
nonparametric variables. For significance testing, the non-
parametric Mann–Whitney U test followed by Bonferroni 
correction was performed. Two-site tests were used for all 
analyses. p values <0.05 were considered significant. Sta-
tistical analysis was performed using SPSS version 18 soft-
ware (SPSS, Inc., IL, USA) and GraphPad Prism software 
5.0 (GraphPad Software Inc., CA, USA).
Results and discussion
Global blood cell analysis showed a generalized low count 
of leukocytes in NF1 patients, independent of age. Granu-
locytes and monocytes are at the lower end of the normal 
range, while lymphocytes are below the standard refer-
ence range (Fig. 1). Our further analysis focused there-
fore on analyzing T cell subpopulations by flow cytometry 
of PBMC from NF1 patients over 18 years (n = 37) and 
healthy age-matched controls (n = 21) (Table 1). As we 
aimed at identifying correlations between the immune phe-
notype and the cancer phenotype, patients were analyzed 
by whole-body MRI to quantify their total internal tumor 
load. Children and NF1 patients below 20 years of age 
were excluded since the tumor phenotype is often not fully 
established at younger ages. No significant differences 
were observed between the overall cohort of NF1 patients 
and the non-NF1 controls for any of the T cell subpopula-
tions (Fig. 2). However, we identified a trend for higher lev-
els of regulatory T cells (Fig. 2a), fewer CD8+/HLA-DR+ 
T cells (Fig. 2b) as well as fewer CD4+CD27− effector T 
cells (Fig. 2e) in the general NF1 population. Although 
these trends were not significant (p = 0.06), the analysis 
clearly revealed groups of patients with very few memory 
and effector T cells (Fig. 2d, e).
Next, we divided the NF1 patients (n = 37) into four 
different groups according to the total internal PNF tumor 
volume as determined by whole-body MRI: The groups 
show no internal tumors (n = 5), low tumor volume 
(n = 11), medium tumor volume (n = 9) and high tumor 
load (n = 11) and associated the frequency of the T cell 
Fig. 1  Blood differential test of NF1 patients. Reference ranges of 
leukocyte populations in samples of healthy subjects are indicated 
by gray boxes. a Adults with NF1 (n = 15, age range 18–68, median 
39 years), b NF1 patients under 18 years (n = 9, age range 4–17, 
median 13 years). The lymphocyte levels are below the normal range 
for both groups (p < 0.05)
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subpopulations with these groups (Fig. 2). We found no 
significant differences between NF1 patients and healthy 
controls or between NF1 patients with different tumor 
loads for any of the CD16/CD56 NK cell populations 
investigated (data not shown). In addition, no associations 
were found between regulatory T cells and the CD4+/HLA-
DR+, CD45RO+, CD57+, and CD27− cell subpopulations, 
as well as the CD8+/HLA-DR+ and CD45RO+ T cell sub-
populations (Fig. 2a–e). In contrast, the CD8+/CD57+ and 
CD8+/CD27− memory and effector T cell populations 
were significantly and inversely correlated with increased 
internal tumor burden of NF1 patients (Fig. 2d, e). The lev-
els dropped even below baseline in the NF1 group with the 
highest tumor load. The association only correlated with 
Table 1  Phenotype of NF1 patients with quantified dermal and internal tumors
* Volume below detection level (1 cm3)
Number of dermal neurofi-
broma
Internal tumor (PNF) (volume in cm3)
Patient no Sex Age Subcutaneous Cutaneous None* Low 1–99 cm3 Medium 100–500 cm3 High >500 cm3 MPNST
1 M 22 1 11–50 x
2 F 40 3 1–10 x
3 M 25 9 0 x
4 F 38 0 101–500 x
5 F 48 11–50 1000+ x
6 F 26 0 11–50 x
7 F 45 51–100 101–500 81
8 F 66 15 11–50 22
9 M 48 0 11–50 39
10 M 44 0 1000+ 28
11 F 55 11–50 101–500 44
12 M 41 0 11–50 16
13 M 42 0 11–50 22
14 M 45 0 51–100 74
15 M 21 0 11–50 38
16 M 27 11–50 11–50 61
17 F 42 0 1000+ 76
18 F 53 0 1000+ 341
19 M 23 2 500+ 119
20 M 25 0 11–50 476
21 F 36 11–50 51–100 326 x
22 F 49 11–50 51–100 382
23 F 26 0 11–50 491
24 M 31 0 11–50 212
25 M 47 11–50 1000+ 115
26 F 35 8 11–50 112
27 M 26 1000+ 1000+ 739 x
28 F 54 0 1000+ 900
29 F 24 0 0 810
30 M 31 10–500 7 5408
31 F 20 1000+ 11–50 950
32 F 50 51–100 1000+ 1191
33 F 34 0 101–500 508
34 M 41 9 1000+ 577
35 M 43 0 8 661
36 F 62 11–50 51–100 1005
37 M 49 0 51–100 767
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Fig. 2  Flow cytometric analysis 
of the ratio between CD4 and 
CD8 cells, and the percentages 
of different T cell populations 
in PBMC samples of healthy 
age- and gender-matched 
controls. a CD4/CD8 ratio and 
regulatory T cells as defined 
by CD4+CD25highCD127low 
phenotype; b frequencies of 
activated HLA-DR+ CD4+ and 
CD8+ cells; c percentages of 
CD45RO+ memory CD4+ and 
CD8+ T cells; d percentages of 
chronically activated CD57+ 
CD4+ and CD8+ T cells and e 
percentages of CD27− effector 
CD4+ and CD8+ T cells
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internal tumor burden and was independent of age (data 
not shown). No correlation was found between lymphocyte 
subpopulations and subcutaneous or cutaneous neurofibro-
mas (data not shown). Although a correlation between the 
growth rate of plexiform and subcutaneous, but not cutane-
ous tumors has been described (27), the data may indicate a 
different role of lymphocytes in internal, subcutaneous and 
cutaneous tumors as compared to PNFs. Other NF1-related 
phenotypes were not quantified in the observed healthy 
and NF1 cohorts, and hence, it was not possible to assess 
associations with vascular, skeletal or cognitive disease 
manifestations.
The results indicate that although not significantly 
different, there is, similar to the significantly different 
D57+ cells, a tendency to also lower frequency of CD8+/
HLA-DR+-activated T cells with increased tumor burden 
(Fig. 2b). However, for CD8+/HLA-DR+-activated T- cells, 
we did not observe an increase from samples of patients 
having no or low tumor volume as observed for CD57+ and 
CD27− cells (Fig. 2b, d, e). This might be due to differ-
ent expression kinetics of the respective maturity stages. 
Interestingly, we did not observe differences in CD45RO+ 
memory T cell frequencies in relation to tumor burden 
(Fig. 2c). Thus, we only observe significant differences 
in frequencies of more terminally differentiated (CD57+/
CD27−) T cells, which show the highest functional capac-
ity, indicating an increasing deficit in T cell differentiation 
with tumor progression.
It is interesting that CD8+CD27− T cells in NF1 patients 
without tumor are lower than in the low tumor group. 
Fig. 3  Intracellular cytokine 
staining after PMA stimula-
tion by CD4 and CD8 cells 
from age- and gender-matched 
NF1 patients (n = 15) and 
healthy controls (n = 13). IL2, 
TNF-α and IFN-γ produc-
tion was determined by FACS 
(*p < 0.05). a Comparison of 
CD4+ and CD8+ fractions; b 
comparison of CD8+/CD57− 
and CD8+/CD57+ fractions
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However, there is a striking increase in frequencies of 
CD8+CD27− T cells from patients with no tumor to low 
tumor, whereas it declines with further tumor progression 
(Fig. 2d, e). We hypothesize that at the beginning of tumor 
formation T cell activation and full differentiation are still 
intact and that the frequencies increase in order to con-
trol the developing tumor. However, during further tumor 
development and at larger tumor volumes, full T cell dif-
ferentiation is inhibited by so far undefined mechanisms 
requiring further investigations in a larger investigation.
CD57 expression is a characteristic of functional 
immune deficiency and replicative senescence [26]. We 
therefore analyzed the capacity of the CD4+ and CD8+/
CD57+ T cells in NF1 patients to secrete inflammatory 
cytokines upon stimulation. Interestingly, IL-2 and IFN-γ 
production is significantly increased in CD8+/CD57+ T 
cells of NF1 patients when compared to healthy controls 
(p < 0.05) (Fig. 3). No difference was found for CD4+/
CD57+ helper T cells. These data suggest that CD8+/
CD57+ replicative exhausted memory T cells in NF1 
patients react strongly to stimulation and produce pro-
inflammatory cytokines at higher levels than control sub-
jects. There was no correlation between tumor load and 
cytokine secretion (data not shown), which is in agreement 
with our previous finding of increased IFN-γ and TNF-α 
serum levels in NF1 patients independently of tumor load 
[23].
NF1 patients with high internal tumor load are at high 
risk for increased morbidity and for development of malig-
nant peripheral nerve sheath tumors (MPNST). The data 
suggest that the level of CD8+/CD57+ and CD27− T cells 
present a useful marker for the internal tumor burden and 
subsequently the risk to transformation into MPNST. Its 
clinical use as such a biomarker alone or together with 
other biomarkers such as insulin-like growth factor binding 
protein 1 (IGFBP1) [23, 24] will need validation in larger 
cohorts.
Our findings potentially also indicate that the T cell-
mediated immune response in patients with low tumor 
load is potentially stronger than in patients with high 
tumor load. Although it would be necessary to substan-
tiate this assumption in a larger cohort, it would suggest 
that patients with high tumor load only mount a weak cel-
lular immune response, favoring the establishment of a 
tumor-promoting environment. The data do not distinguish 
between the alternative hypotheses that aberrant immune 
cell counts are the consequence rather than a cause of the 
variable systemic tumor phenotype in NF1 patients. For 
example, a large tumor burden might increasingly exhaust 
the existing effector CD57+ T cell reservoir. Interest-
ingly, an increased number of CD8+CD57+ T cells in NF1 
patients was also shown in another study [16], although 
our data confirm such an increase only for the NF1 
subgroups with low or medium internal tumor load. It is of 
note that the CD8+/CD27− populations in the NF1 group 
without internal tumors were smaller than in any other 
subgroup, including the healthy control group. The aber-
rantly low levels of this T cell population were thus not 
dependent on tumors and caused by the tumor phenotype. 
Although the group size is too small for statistically useful 
evaluation, this trend may suggest a general difference in 
the T cell phenotype of NF1 patients.
In conclusion, our results show that the CD8 memory 
and effector T cell levels are inversely correlated with 
tumor burden in NF1 patients. Hence, the ratios of CD8+/
CD57+ and CD27− T cells may present a useful surro-
gate marker for the internal tumor burden of NF1 patients, 
which justifies further validation in a larger cohort.
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